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The WHO 2008 definition of chronic neutrophilic leukemia (CNL) is based on clinical and laboratory parameters but
not on molecular abnormalities. Mutations in CSF3R, SETBP1 and CALR are reported in patients with chronic
neutrophilic leukemia (CNL). However, because CNL is rare, there are few large studies of this issue. We sequenced
these genes in 14 patients who met the WHO-criteria of CNL. 8 subjects had CSF3RT618I, 6 SETBP1 mutations and 1 a
CALR mutation. Our data suggest mutation analysis of CSF3R, SETBP1 and CALR should be included in the diagnostic
criteria for CNL. These data may also have therapy implications.
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The WHO defines chronic neutrophilic leukemia (CNL)
as a myeloproliferative neoplasm (MPN) with sustained el-
evated neutrophils and <10% immature cells [1]. Recently,
recurrent somatic mutations in the membrane proximal
domain of CSF3R were reported in patients with CNL
[2,3]. CSF3R was mutated in 100% [3], SETBP1 33% [3]
and CALR in 12.5% of WHO-defined cases of CNL [4].
We analyzed mutations in CSF3R, SETBP1 and CALR in
14 subjects who met the WHO-criteria.Findings
CSF3R exon 14–17 [3], SETBP1 exon 4 [3] and CALR
exon 9 [5] were amplified by PCR and sequenced. 8
subjects who met the WHO 2008 CNL criteria had a
CSF3RT618I mutation, 6 SETBP1 mutations (2 D868N, 2
I871T, 1 G870S and 1 D874N) and the last had a CALR
mutation (c.1154-1155insTTGTC). All mutations were
heterozygous except 1 case of SETBP1I871T. 6 other
subjects, 2 with monoclonal gammopathy of unknown
significance (MGUS)-associated CNL and 4 with* Correspondence: zjxiao@medmail.com.cn
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unless otherwise stated.reactive neutrophilic leukocytosis had no mutation of these
genes. No subject had a JAK2V617F mutation (Table 1).
The consistent association between CSF3RT618I and
CNL in our study is similar to data of Maxson et al. [2]
and Pardanani et al. [3] (Table 2). Tefferi et al. [6] sug-
gested including CSF3RT618I or other membrane proximal
CSF3R mutations as a criteria for diagnosis of CNL. We
also confirmed the high incidence SETBP1 mutations in
patients with CNL. The mutations we detected focused on
a hotspot area from D868 to D874 (Table 1). Although
these mutations also occur in other hematologic neo-
plasms such as atypical chronic myeloid leukemia aCML
and chronic myelomonocytic leukemia (CMML), analysis
of SETBP1 mutations could help distinguish CNL from re-
active conditions such as infection, inflammatory condi-
tions and non-haematologic neoplasms.
Gotlib et al. reported JAK2V617F mutation in a sub-
ject of CNL [7]. Lasho et al. reported a CALR mis-
sense mutation in a subject with CNL [4]. We found
concurrent CSF3RT618I and CALR frame-shift muta-
tions in 1 subject. The 5 bp insertion into CALR exon
9 is reported in BCR/ABL1- and JAK2-negative MPNs
and results in a 1+ base-pair frame-shift with an altered
C-terminus.
There is controversy whether co-existence of MGUS
and CNL is one or two diseases. The 2 MGUS subjects
in our study had no mutation in CSF3R, SETBP1, JAK2
or CALR. In another study, none of 6 cases of MGUS-. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Clinical characteristics and laboratory variables
No. Diagnosis Gender/Age Hb (g/L) WBC (×109/L) ANC (×109/L) PLT (×109/L) Spleen (cm,LCM) Karyotypes CSF3R SETBP1 CALR JAK2V617F Treatment Survival
(month)
1 CNL M/80 120 27.19 25.42 91 3 46,XY,t(1,7)
(p32,q11)[10]
T618I D874N wt wt Hydroxyurea 52
2 CNL M/64 123 86.83 ND 394 0 46,XY[5] T618I D868N wt wt Hydroxyurea 5+
3 CNL F/77 125 35.68 25.92 351 4 46,XY[20] T618I G870S wt wt Hydroxyurea 22+
4 CNL F/49 104 85.61 79.47 20 6 46,XX[20] T618I I871T wt wt Hydroxyurea 13+
5 CNL M/70 86 146.77 121.82 104 15 ND T618I I871T wt wt Hydroxyurea 17
6 CNL M/43 55 112.65 101.1 98 10 46,XY[5] T618I D868N wt wt Hydroxyurea 4+
7 CNL F/69 102 57.40 40.16 231 6 46,XX[12] T618I wt c.1154-
1155insTTGTC
wt Hydroxyurea 10
8 CNL M/45 119 32.76 28.73 286 6 46,XY[9] T618I wt wt wt Hydroxyurea 32
9 MGUS-CNL M/46 63 65.30 60.7 101 7 46,XY[2] wt wt wt wt Hydroxyurea 6+
10 MGUS-CNL F/52 121 26.53 19.94 170 3 46,XX[20] wt wt wt wt Hydroxyurea 27+
All the parameters in Table 1 were measured at the initial diagnosis in our hospital.
MGUS-CNL: monoclonal gammopathy with uncertain significance associated CNL; Hb: hemoglobin; WBC: White Blood Cell Count; ANC: Absolute Neutrophil Count; PLT: Platelet Count; Spleen (cm): Spleen size under



















Table 2 CSF3R and SETBP1 mutations in CNL
Gotlib J et al.
(2013) [7]
Pardanani A




T618I only 1 5 1 7
T618I + SETBP1 4 4 6 14
Compound CSF3R
mutationsa only




1 0 0 1
Others 1b 2c 1d 4
a: compound CSF3R mutations mean nonsense or frameshift mutations that
truncate the cytoplasmic tail (truncation mutations) combined with point
mutations in the extracellular domain (membrane proximal mutation). In the 3
cases of compound CSF3R mutations Tyner et al. reported, two patients
harbored T618I and one harbored T615A in the membrane proximal domain.
In Tefferi’s study, the compound CSF3R mutation
showed T618I + c.2341_2342insC.
b: A case with JAK2 mutation only.
c: A case with I598I and a case with M696T in CSF3R.
d: A case with CSF3R T618I and CALR frameshift mutation.
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http://www.jhoonline.org/content/7/1/77associated CNL had CSF3R mutations [3]. Also, survival
of patients with MGUS-associated CNL is significantly
longer survival than those with CNL only. These data
support the notion patients with MGUS and CNL are 2
diseases [8].
There may be therapy implications of our findings.
CSF3R truncation mutations may be sensitive to SRC
kinase-inhibitors such as dasatinib whereas CSF3R
membrane proximal mutations may be sensitive to JAK
kinase-inhibitors such as ruxolitinib [9,10]. Ruxolitinib
was reportedly effective in a mouse model of CNL and
a patient with CNL and a CSF3RT618I mutation [2,11].
However, ruxolitinib was ineffective in a patient with
CSF3RT618I and SETBP1 mutations in whom fedratinib
suppressed CFU-GM colony formation [12].
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